On October 10, 2024, AIML reported an impairment loss of $1,510,668, following an internal assessment of its investment in T2H. While T2H had achieved modest growth, AIML determined that the company ...
These patents strengthen AIML's position in the growing field of AI-assisted cardiology by protecting both the algorithmic foundations and the applied deployment stack of its technology. The dynamic ...
VANCOUVER, BC / ACCESS Newswire / August 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is issuing the following press release to clarify its disclosure ...
Restructured agreement increases capital efficiency, simplifies revenue structure, and expands future opportunity. VANCOUVER, BC / ACCESS Newswire / April 25, 2025 / AI/ML Innovations Inc. ("AIML" or ...
TORONTO, ON / ACCESS Newswire / December 30, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has announced that its consulting agreement with Campfire ...
Medical Advisory Board will guide clinical studies, regulatory strategy, and global adoption of AIML's AI‑driven ECG signal‑processing solutions MaxYield™ and CardioYield™ across wearables and ...
AIML Appoints Dr. Paul Dorian as Medical Innovation Architect and Head of the Medical Advisory Board
TORONTO, ON / ACCESS Newswire / January 28, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the appointment of Dr. Paul Dorian, MD, MSc ...
VANCOUVER, BC / ACCESS Newswire / March 21, 2025 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce the execution of a formal exit agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results